Moneycontrol PRO
you are here: HomeNewsBusiness

Indian domestic passenger traffic was 49.6% lower in November: IATA

The IATA, which represents around 290 airlines comprising 82 percent of global air traffic, measures passenger growth in revenue passenger kilometres (RPKs), which is calculated by multiplying the number of passengers to the distance travelled by them.

January 07, 2021 / 10:20 PM IST

Domestic passenger traffic growth in India was 49.6 percent lower in November last year as compared to the corresponding month in 2019, said global airlines body IATA on Thursday.

"In India, domestic RPKs contracted by 49.6% year-on-year in November vs. 55.6% fall in October. A further improvement is expected in the near-term as more schools and businesses reopen," said a report issued by the International Air Transport Association (IATA).

The IATA, which represents around 290 airlines comprising 82 percent of global air traffic, measures passenger growth in revenue passenger kilometres (RPKs), which is calculated by multiplying the number of passengers to the distance travelled by them.

Scheduled domestic passenger flights resumed in India on May 25 last year after a gap of two months due to the coronavirus-induced lockdown.

Currently, Indian carriers are permitted to operate 80 percent of their pre-COVID domestic flights.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Follow our full coverage of the coronavirus pandemic here.
PTI
first published: Jan 7, 2021 10:22 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark